MIM PHARMA was established in 2009 by the goal of creating a curative drug for migraine disease. After many years of rigorous research and large clinical trials at the only migraine clinic in the Middle East, Mim Pharma Company introduced its first medicine for migraine headaches in 2013. In the beginning, the drug was in the shape of powder and was to be processed and inhaled by the migraine patients in special apparatus in clinics. It was expensive and not available to most patients. After many years of rigorous research to make the drug easy-to-use and available to all, the R&D team of Mim Pharma developed a new version of migraine medicine. In 2019, Migraine Spray passed all the requirements and clinical trials that were performed based on the International headache society (IHS) guidelines on 300 patients.
Further, MIM PHARMA is working in herbal and Nature-based treatments for common annoying diseases such as Allergy, Eczema, Sinusitis, and ... and there search and development team have achieved very promising results in treating these diseases.
To transfer the legacy of deep-rooted natural medicine to the modern pharmaceutical R&D and manufacturing techniques for introducing novel products
To help humanity get rid of common and widespread ailments such as migraine headaches, allergies, skin injuries, and sinusitis.
To be an R&D-oriented pharmaceutical company by applying the most up-to-date technology, techniques, and quality
To introduce novel products to theworld
To remove or mitigate pain and ailments using natural products
To create a scientific, energetic, and entrepreneurial organization that contributes to the improvement of improving human health
To emphasize on innovation and continuous improvement both in the processes and products
To commit to the well-being of mankind, especially the patients
To act ethically and treat all with honesty and respect
Our R&D team comprises brilliant and distinguished researches with very rich backgrounds.
We own a multi-disciplinary clinic where the clinical trials on our novel products are carried out